The FDA granted QIDP designation to Talicia, an FDA-approved rifabutin-based product, on August 18, 2025. Rick Scruggs is President and CCO of RedHill Biopharma Ltd.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted QIDP designation to Talicia, an FDA-approved rifabutin-based product, on August 18, 2025. Rick Scruggs is President and CCO of RedHill Biopharma Ltd.
Who's involved
What this event is mainly aboutFDARick Scruggs
How it developed
Newest first. Tap a step to see who reported it.- Apotex acquired the Talicia business from RedHill Biopharma Ltd., which focuses on targeting H. pylori infection.Sub-event
FDA grants QIDP designation to Talicia, a rifabutin-based product, from RedHill Biopharma.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- PR NewswireRedHill Received Talicia® Licensing Payments Totaling $1.1 Million RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, follo